Company research / IMRX

Immuneering Corp (IMRX)

CIK 0001790340 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2023-12-31, Immuneering Corp reported revenue of $0. Revenue fell 100.0% from the prior annual period.

Key ratios (year ended 2023-12-31)

-59.0%
Return on year-end equity
-100.0%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 10-Q · 2026-08-05

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.